ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 1437

Journal of Clinical & Experimental Pathology received 1437 citations as per Google Scholar report

Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Cosmos IF
  • Ulrich's Periodicals Directory
  • RefSeek
  • Directory of Research Journal Indexing (DRJI)
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
  • world cat
  • journal seek genamics
  • j-gate
  • esji (eurasian scientific journal index)
Share This Page

Estimation of stem cell frequency in acute myeloid leukemia at diagnosis: Relation to hematological and clinical parameters

9th World Digital Pathology & Pathologists Congress

Eman Kandeel

Cairo University, Egypt

ScientificTracks Abstracts: J Clin Exp Pathol

DOI: 10.4172/2161-0681.C1.028

Abstract
Background: Acute myeloid leukemia (AML) outcome is inferior to acute lymphoblastic leukemia. Treatment failure is largely attributed to the persistence of leukemia stem cells (LSCs) which are less accessible and hence less responsive to chemotherapeutics. Aim: To demonstrate the impact of LSCs frequency at diagnosis and at follow up periods as compared to minimal residual disease (MRD) on overall survival (OS) and disease free survival (DFS). Methods: The study was performed on 84 adult AML patients. Panels used CD38FITC/CD123PE/CD34ECD/CD45PE-PC5 and CD90FITC/CD133PE/CD45ECD/CD33PE-PC5 analyzed on Navios Flow cytometer. Cell populations with different surface markers were calculated using the prism function of the software. The study was performed according to Helsinki declaration for studies on human subjects and approved by the Institution Review Board (IRB) of the National Cancer Institute, Cairo University. An informed signed consent was obtained from all study subjects before enrollment. Results: A higher CD 123% at diagnosis (pâ�?¤0.001) and at day (d) 14 (p=0.004 & pâ�?¤0.001 respectively) had an adverse impact on OS and DFS. A higher CD 133% at diagnosis and at d14 (P=0.006 & Pâ�?¤0.001 and Pâ�?¤0.001 & Pâ�?¤0.001 respectively), had an adverse impact on OS and DFS. A higher [CD34-/CD38+/CD123+] percentage at diagnosis (P=0.025 and Pâ�?¤0.001) had adverse impact on OS and DFS at d14 (P=0.029) had adverse impact only on DFS. Conclusion: High frequency of LSCs reflects a higher percentage of chemotherapy resistant cells that will lead to the outgrowth of MRD, thereby affecting clinical outcome.
Biography

Eman Kandeel has completed her MD in 2011 from NCI, Cairo University, Egypt. She has experience of Flow Cytometry from Roswell Park Cancer Institute, Buffalo, New York. She is a Lecturer at BMT lab Clinical Pathology Department from 2011 to till date.

Email: eman_zaghloul@yahoo.com

Top